Clinical trials in DO NOT EDIT

2 clinical trials in DO NOT EDIT, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

DO NOT EDIT at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

2 trials in DO NOT EDIT

Open in trial search

Triple negative breast cancer+4

Recruiting

Registered drugNo placebo

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Neoplasm

Not yet recruiting

Registered drugNo placebo

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in DO NOT EDIT

What the registry says about research in the country

01 DO NOT EDIT

Solid Tumors

In the city, investigators are conducting early‑stage studies aimed at establishing the safety and tolerability of a novel agent, TER-2013, both as a single treatment and in combination with estrogen‑receptor targeting drugs. Safety and maximum tolerated dose assessment Combination strategies with estrogen‑receptor antagonists Preliminary efficacy signals in advanced disease The trials are actively recruiting and seek to accelerate therapeutic options for patients with diverse solid‑tumor profiles.

Triple‑negative Early Breast Cancer

A separate investigation focuses on neoadjuvant personalized therapy that pairs sacituzumab govitecan with pembrolizumab, comparing outcomes to standard chemotherapy in stage II‑III disease. Evaluation of three‑year event‑free survival Assessment of pathological complete response rates Dynamic biomarker‑guided treatment adaptation This recruiting study aims to improve cure rates for patients with this aggressive breast cancer subtype.

Back to Poland All countries